Top 20% of endocrinologists write lion's share of new oral diabetes scripts: SDI

Share this article:

Choosing which doctors to target when promoting a new product is essential to success, since most doctors are less likely to start prescribing your drug.

According to an SDI report, 20% of endocrinologists were responsible for prescribing 95% of new-to-brand oral diabetes therapies from September 2007 through August 2008. With primary care prescribers, the top 30% were accountable for 90% of new-to-brand scripts in this group.

The report measured oral diabetes-indicated products, including sulfonylureas, meglitinides, amino acid derivatives, biguanides, insulin sensitizers and alpha-glucos inhibitors, according to Tracy Everly, marketing publications writer, SDI.

In order to maximize the efficiency of physician marketing, companies have to reach these key drivers of market growth. “The traditional method of evaluating prescribers based on total prescriptions, which include renewals and refills, does not accurately identify customer segments that have the most influence on generating new market volume,” SDI said in a statement. “Utilizing SDI patient-level data, pharmaceutical companies can identify prescribers most likely to drive new prescription volume, enabling them to refine their promotional strategies and improve field sales force performance.”  

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.